BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35746644)

  • 1. A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine.
    Feng H; Sun R; Song G; Zhu S; Nie Z; Lin L; Yi R; Wu S; Wang G; He Y; Wang S; Wang P; Wu L; Shu J
    Viruses; 2022 May; 14(6):. PubMed ID: 35746644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
    Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice.
    Feng H; Nakajima N; Wu L; Yamashita M; Lopes TJS; Tsuji M; Hasegawa H; Watanabe T; Kawaoka Y
    Front Microbiol; 2019; 10():2157. PubMed ID: 31620111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.
    Kim ED; Han SJ; Byun YH; Yoon SC; Choi KS; Seong BL; Seo KY
    PLoS One; 2015; 10(9):e0137608. PubMed ID: 26355295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H; Bao Y; Wang X; Zhou D; Wu W
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
    Falkeborn T; Bråve A; Larsson M; Akerlind B; Schröder U; Hinkula J
    PLoS One; 2013; 8(8):e70527. PubMed ID: 23950951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal co-administration of 1,8-cineole with influenza vaccine provide cross-protection against influenza virus infection.
    Li Y; Xu YL; Lai YN; Liao SH; Liu N; Xu PP
    Phytomedicine; 2017 Oct; 34():127-135. PubMed ID: 28899494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.
    Kopecky-Bromberg SA; Fraser KA; Pica N; Carnero E; Moran TM; Franck RW; Tsuji M; Palese P
    Vaccine; 2009 Jun; 27(28):3766-74. PubMed ID: 19464560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection.
    Kusakabe T; Ozasa K; Kobari S; Momota M; Kishishita N; Kobiyama K; Kuroda E; Ishii KJ
    Vaccine; 2016 Jun; 34(27):3191-3198. PubMed ID: 27160037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
    Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
    Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.